1 - 25 of 37 results for author:"Coetzee G.A." in Literature citations
Results Customize
› Repeat search in UniProtKB (2)
| Subdomain structure of the co-chaperone SGTA and activity of its androgen receptor client. Trotta A.P., Need E.F., Butler L.M., Selth L.A., O'Loughlin M.A., Coetzee G.A., Tilley W.D., Buchanan G. J. Mol. Endocrinol. 49:57-68(2012) · Mapped (2) |
| An enhancer from the 8q24 prostate cancer risk region is sufficient to direct reporter gene expression to a subset of prostate stem-like epithelial cells in transgenic mice. Ting M.C., Liao C.P., Yan C., Jia L., Groshen S., Frenkel B., Roy-Burman P., Coetzee G.A., Maxson R. Dis Model Mech 5:366-374(2012) · Mapped (5) |
| Shorter androgen receptor CAG repeat lengths associated with cryptorchidism risk among Hispanic white boys. Davis-Dao C., Koh C.J., Hardy B.E., Chang A., Kim S.S., De Filippo R., Hwang A., Pike M.C., Carroll J.D., Coetzee G.A. et al. J. Clin. Endocrinol. Metab. 97:E393-9(2012) · Mapped (11) |
| Heterogenous effect of androgen receptor CAG tract length on testicular germ cell tumor risk: shorter repeats associated with seminoma but not other histologic types. Davis-Dao C.A., Siegmund K.D., Vandenberg D.J., Skinner E.C., Coetzee G.A., Thomas D.C., Pike M.C., Cortessis V.K. Carcinogenesis 32:1238-1243(2011) · Mapped (11) |
| TPL2/COT/MAP3K8 (TPL2) activation promotes androgen depletion-independent (ADI) prostate cancer growth. Jeong J.H., Bhatia A., Toth Z., Oh S., Inn K.S., Liao C.P., Roy-Burman P., Melamed J., Coetzee G.A., Jung J.U. PLoS ONE 6:e16205-e16205(2011) · Mapped (4) |
| Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Baniwal S.K., Khalid O., Gabet Y., Shah R.R., Purcell D.J., Mav D., Kohn-Gabet A.E., Shi Y., Coetzee G.A., Frenkel B. Mol. Cancer 9:258-258(2010) · Mapped (5) |
| Hypertension, diuretics and antihypertensives in relation to bladder cancer. Jiang X., Castelao J.E., Yuan J.M., Groshen S., Stern M.C., Conti D.V., Cortessis V.K., Coetzee G.A., Pike M.C., Gago-Dominguez M. Carcinogenesis 31:1964-1971(2010) · Mapped (2) |
| 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Ahmadiyeh N., Pomerantz M.M., Grisanzio C., Herman P., Jia L., Almendro V., He H.H., Brown M., Liu X.S., Davis M. et al. Proc. Natl. Acad. Sci. U.S.A. 107:9742-9746(2010) · Mapped (7) |
| The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Pomerantz M.M., Ahmadiyeh N., Jia L., Herman P., Verzi M.P., Doddapaneni H., Beckwith C.A., Chan J.A., Hills A., Davis M. et al. Nat. Genet. 41:882-884(2009) · Mapped (7) |
| Repression of Runx2 by androgen receptor (AR) in osteoblasts and prostate cancer cells: AR binds Runx2 and abrogates its recruitment to DNA. Baniwal S.K., Khalid O., Sir D., Buchanan G., Coetzee G.A., Frenkel B. Mol. Endocrinol. 23:1203-1214(2009) · Mapped (21) |
| Inhibition of AR-mediated transcription by binding of Oct1 to a motif enriched in AR-occupied regions. Jariwala U., Cogan J.P., Jia L., Frenkel B., Coetzee G.A. Prostate 69:392-400(2009) · Mapped (16) |
| Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. Jia L., Berman B.P., Jariwala U., Yan X., Cogan J.P., Walters A., Chen T., Buchanan G., Frenkel B., Coetzee G.A. PLoS ONE 3:e3645-e3645(2008) · Mapped (11) |
| Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer. Yuan J.M., Chan K.K., Coetzee G.A., Castelao J.E., Watson M.A., Bell D.A., Wang R., Yu M.C. Carcinogenesis 29:1386-1393(2008) · Mapped (51) |
| Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. Buchanan G., Ricciardelli C., Harris J.M., Prescott J., Yu Z.C., Jia L., Butler L.M., Marshall V.R., Scher H.I., Gerald W.L. et al. Cancer Res. 67:10087-10096(2007) · Mapped (2) |
| Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. Cozen W., Gebregziabher M., Conti D.V., Van Den Berg D.J., Coetzee G.A., Wang S.S., Rothman N., Bernstein L., Hartge P., Morhbacher A. et al. Cancer Epidemiol. Biomarkers Prev. 15:2285-2291(2006) · Mapped (5) |
| Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells. Jia L., Shen H.C., Wantroba M., Khalid O., Liang G., Wang Q., Gentzschein E., Pinski J.K., Stanczyk F.Z., Jones P.A. et al. Mol. Cell. Biol. 26:7331-7341(2006) · Mapped (11) |
| Molecular chaperones throughout the life cycle of the androgen receptor. Prescott J., Coetzee G.A. Cancer Lett. 231:12-19(2006) · Mapped (10) |
| Carotenoids/vitamin C and smoking-related bladder cancer. Castelao J.E., Yuan J.M., Gago-Dominguez M., Skipper P.L., Tannenbaum S.R., Chan K.K., Watson M.A., Bell D.A., Coetzee G.A., Ross R.K. et al. Int. J. Cancer 110:417-423(2004) · Mapped (21) |
| Dynamic methylation of histone H3 at lysine 4 in transcriptional regulation by the androgen receptor. Kim J., Jia L., Tilley W.D., Coetzee G.A. Nucleic Acids Res. 31:6741-6747(2003) · Mapped (11) |
| Permanent hair dyes and bladder cancer: risk modification by cytochrome P4501A2 and N-acetyltransferases 1 and 2. Gago-Dominguez M., Bell D.A., Watson M.A., Yuan J.M., Castelao J.E., Hein D.W., Chan K.K., Coetzee G.A., Ross R.K., Yu M.C. Carcinogenesis 24:483-489(2003) · Mapped (3) |
| Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. Jia L., Kim J., Shen H., Clark P.E., Tilley W.D., Coetzee G.A. Mol. Cancer Res. 1:385-392(2003) · Mapped (11) |
| Thymidylate synthase: a novel genetic determinant of plasma homocysteine and folate levels. Trinh B.N., Ong C.N., Coetzee G.A., Yu M.C., Laird P.W. Hum. Genet. 111:299-302(2002) · Mapped (12) |
| Vitamin D receptor polymorphisms and risk of colorectal adenomas (United States). Ingles S.A., Wang J., Coetzee G.A., Lee E.R., Frankl H.D., Haile R.W. Cancer Causes Control 12:607-614(2001) · Mapped (6) |
| Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype. McKean-Cowdin R., Feigelson H.S., Pike M.C., Coetzee G.A., Kolonel L.N., Henderson B.E. Cancer Res. 61:848-849(2001) · Mapped (3) |
| Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Feigelson H.S., McKean-Cowdin R., Coetzee G.A., Stram D.O., Kolonel L.N., Henderson B.E. Cancer Res. 61:785-789(2001) · Mapped (10) |